medigraphic.com
ISSN 2448-8747 (Print)
Publicación cuatrimestral editada por la Secretaría de Salud Jalisco

2022, Number 1

<< Back Next >>

Sal Jal 2022; 9 (1)

Síndromes neuropsiquiátricos asociados a encefalitis autoinmune

López-Sandoval MA, Aldana-López JA

Language: Spanish
References: 47
Page: 35-44
PDF size: 283.67 Kb.


ABSTRACT

Autoimmune encephalitis are rare conditions in which neuronal antibodies produce severe inflammation of the brain, clinical manifestations include a wide variety ranging from epilepsy to movement disorder and some types of psychiatric syndromes; it may affect adults and pediatric population, and are related to different etiologies (neoplasic, infectious and cryptogenic). Despite of being considered rare conditions, it’s clinical suspicion as well as being considered as a differential diagnosis, may provide the early management with immunotherapy, that in combination of autoantibodies titer are the most relevant prognostic features in the course of this illness. This article summarize the pathophysiologic features, the clinical manifestations of the neuropsychiatric syndromes associated to antineuronal antibodies, the diagnostic and therapeutic approach


REFERENCES

  1. Honnorat J, Didelot A, Karantoni E, Ville D, Ducray F, Lambert L, et al. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology. 2013 ;80(24): 2226–2232.

  2. Gable M, Sheriff H, Dalmau J, Tilley D, Glaser C. Th e frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clinical infectious diseases: an offi cial publication of the Infectious Diseases Society of America. 2012; 54(7): 899–904.

  3. Goodfellow J, Mackay G. Autoimmune encephalitis. Th e journal of the Royal College of Physicians of Edinburgh. 2019; 49(4):287– 294.

  4. Granerod J, Ambrose H, Davies N, Clewley J, Walsh A, Morgan D, et al. Aetiology of Encephalitis Study Group. Causes of encephalitis and diff erences in their clinical presentations in England: a multicentre, population-based prospective study. Th e Lancet. Infectious diseases. 2010;10(12): 835–844.

  5. Graus F, Titulaer M, Balu R, Benseler S, Bien C, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Th e Lancet. Neurology. 2016; 15(4): 391–404.

  6. Linnoila J, Binnicker M, Majed M, Klein C, McKeon A. CSF herpes virus and autoantibody profi les in the evaluation of encephalitis. Neurology(R) neuroimmunology & neuroinfl ammation [Internet]. 2016 [Consultado el 22 de septiembre de 2020]; 3(4). Disponible en: https://doi.org/10.1212/NXI.0000000000000245

  7. Lancaster E. Th e Diagnosis and Treatment of Autoimmune Encephalitis. Journal of clinical neurology (Seoul, Korea). 2016; 12(1): 1–13.

  8. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld M, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Th e Lancet. Neurology. 2011; 10(1): 63–74.

  9. Armangue T, Titulaer M, Málaga I, Bataller L, Gabilondo I, Graus F, Dalmau J. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel fi ndings in a series of 20 patients. Th e Journal of pediatrics. 2013; 162(4): 850–856.

  10. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the eff ects of antibodies. Th e Lancet. Neurology. 2008; 7(12): 1091–1098. https://doi.org/10.1016/S1474-4422(08)70224-2

  11. Fenalti G, y Rowley MJ. GAD65 as a prototypic autoantigen. Journal of autoimmunity. 2008; 31(3): 228–232.

  12. Irani S, Stagg C, Schott J, Rosenthal, C, Schneider S, Pettingill P. Faciobrachial dystonic seizures: the infl uence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain : a journal of neurology. 2013;136(10): 3151–3162.

  13. Rojas I, Graus F, Keime-Guibert F, Reñé R, Delattre JY, Ramón Jm et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000; 55(5): 713–715.

  14. Isaacs H. A syndrome of continuous muscle-fi bre activity. Journal of neurology, neurosurgery, and psychiatry. 1961; 24(4): 319–325.

  15. Isaacs H. Continuous muscle fi bre activity in an Indian male with additional evidence of terminal motor fi bre abnormality. Journal of neurology. neurosurgery, and psychiatry, 1937; 30(2): 126–133.

  16. van Coevorden-Hameete M, de Graaff E, Titulaer M, Hoogenraad C , Sillevis-Smitt P. Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system. Autoimmunity reviews. 2014; 13(3): 299–312.

  17. Leypoldt F, Wandinger K, Bien C, Dalmau J. Autoimmune Encephalitis. European neurological review. 2013; 8(1): 31–37.

  18. Prüß H. Pathophysiologie und Prognosefaktoren der Autoimmunenzephalitiden [Pathophysiology and Prognostic Factors of Autoimmune Encephalitis]. Fortschritte der Neurologie- Psychiatrie. 2016; 84(5): 264–270.

  19. Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Th e Lancet. Neurology. 2013; 12(2): 157–165.

  20. Fukata, M., Yokoi, N., y Fukata, Y. Neurobiology of autoimmune encephalitis. Current opinion in neurobiology. 2018; 48: 1–8.

  21. Dutra LA, Abrantes F, Toso FF, Pedroso JL, Barsottini O, Hoft berger R. Autoimmune encephalitis: a review of diagnosis and treatment. Arquivos de neuro-psiquiatria. 2018; 76(1): 41–49.

  22. Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A, Martinez- Hernandez E, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Annals of neurology. 2011; 69(2): 303–311.

  23. van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ. Th e value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nature reviews. Neurology. 2017; 13(5): 290–301.

  24. Saint-Martin M, Pieters A, Déchelotte B, Malleval C, Pinatel D, Pascual O, et al. (septiembre, 2019). Impact of anti-CASPR2 autoantibodies from patients with autoimmune encephalitis on CASPR2/TAG-1 interaction and Kv1 expression. Journal of autoimmunity. 2019; 103, 102-284.

  25. Irani S, Michell A, Lang B, Pettingill P, Waters P, Johnson M, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Annals of neurology. 2011; 69(5): 892–900.

  26. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Annals of neurology. 2009; 65(4): 424–434.

  27. Höft berger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind M, Gelfand J, et al. Encephalitis and AMPA receptor antibodies: Novel fi ndings in a case series of 22 patients. Neurology. 2015; 84(24): 2403–2412.

  28. Gresa-Arribas N, Ariño H, Martínez-Hernández E, Petit-Pedrol M, Sabater L, Saiz A, et al. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PloS one [Internet] 2015 [Consultado el 22 de septiembre de 2020]; 10(3): e0121364. Dispomible en: https://doi.org/10.1371/journal.pone.0121364

  29. Muñoz-Lopetegi A, de Bruijn M, Boukhrissi S, Bastiaansen A, Nagtzaam M, Hulsenboom, E, Boon A, et al. Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment. Neurology(R) neuroimmunology & neuroinfl ammation[Internet]. 2020 [Consultado el 23 de septiembre de 2020]; 7(3): e696. Disponible en: https://doi. org/10.1212/NXI.0000000000000696.

  30. Ariño H, Höft berger R, Gresa-Arribas N, Martínez-Hernández E, Armangue T, Kruer MC, et al. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies. JAMA neurology. 2015; 72(8): 874–881.

  31. Brieva-Ruíz L, Diaz-Hurtado M, Matias-Guiu X, Márquez- Medina D, Tarragona J, Graus F. Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study. Clinical neurology and neurosurgery. 2008; 110(10): 1044–1046. https://doi.org/10.1016/j.clineuro.2008.06.016

  32. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Annals of neurology. 2001; 50(3): 301–311.

  33. Peterson K, Rosenblum, MK, Kotanides H, y Posner, JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992; 42(10): 1931–1937.

  34. Venkatesan A, Tunkel, AR, Bloch KC, Lauring AS, Sejvar J, Bitnun A, et al. Case defi nitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clinical infectious diseases :an offi cial publication of the Infectious Diseases Society of America. 2013; 57(8): 1114– 1128.

  35. Solomon T, Michael BD, Smith PE, Sanderson F, Davies NW, Hart IJ, et al. Management of suspected viral encephalitis in adults--Association of British Neurologists and British Infection Association National Guidelines. Th e Journal of infection. 2012; 64(4): 347–373.

  36. Kaplan PW, Rossetti AO. EEG patterns and imaging correlations in encephalopathy: encephalopathy part II. Journal of clinical neurophysiology : offi cial publication of the American Electroencephalographic Society,. 2011; 28(3): 233–251.

  37. Nosadini M, Boniver C, Zuliani L, de Palma L, Cainelli E, Battistella PA, Toldo I, et al. Longitudinal electroencephalographic (EEG) fi ndings in pediatric anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis: the Padua experience. Journal of child neurology. 2015; 30(2): 238–245.

  38. Vincent A, Bien, CG, Irani, SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Th e Lancet. Neurology. 2011; 10(8): 759–772.

  39. Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, Graus F, et al. Th e expanding fi eld of IgG4-mediated neurological autoimmune disorders. European journal of neurology. 2015; 22(8):1151–1161.

  40. Fassbender C, Klingel R, Köhler W. (noviembre, 2017). Immunoadsorption for autoimmune encephalitis. Atherosclerosis. Supplements. 2017; 30: 257–263.

  41. Moscato EH, Jain A, Peng X, Hughes EG, Dalmau J, Balice- Gordon RJ. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. The European journal of neuroscience. 2010; 32(2): 298–309.

  42. Dogan OM, Golombeck KS, Bien C, Abu-Tair M, Brand M, Bulla-Hellwig M, et al. Immunoadsorption therapy in autoimmune encephalitides. Neurology(R) neuroimmunology & neuroinfl ammation [Internet] 2016 [Consultado el 23 de septiembre de 2020]; 3(2): e207. Disponible en: https://doi. org/10.1212/NXI.0000000000000207.

  43. Dalmau, J. Th e Role of Synaptic Autoantibodies in Psychiatric Disease; 2020 Abr 25-26; American Psychiatric Association, Spring Highlights Meeting 2020, Disponible en: https://www. psychiatry.org/psychiatrists/meetings/spring-highlights

  44. Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. Journal of neurology, neurosurgery, and psychiatry. 2007; 78(4): 381–385.

  45. Balu R, McCracken L, Lancaster E, Graus F, Dalmau J, Titulaer, MJ. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology [Internet] 2019[ Consultado el 23 de septiembre de 2020]; 92(3):e244–e252. Disponible en: https://doi.org/10.1212/WNL.0000000000006783

  46. Chavez-Castillo M, Ruiz-Garcia M, Herrera-Mora P. Characterization and Outcomes of Epileptic Seizures in Mexican Pediatric Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Cureus [Internet] 2020 [Consultado el 28 de septiembre de 2020]; 12(5): e8211. Disponible en: https://doi. org/10.7759/cureus.8211

  47. Broadley J, Seneviratne U, Beech P, Buzzard K, Butzkueven H, O’Brien T, et al. Prognosticating autoimmune encephalitis: A systematic review. Journal of autoimmunity 2019; 96:24–34.




2020     |     www.medigraphic.com